Balance Sheet Components

6 Months Ended

Jun. 30, 2026

Balance Sheet Related Disclosures [Abstract]

Goodwill

Goodwill was $767.2 million as of both June 30, 2026 and December 31, 2025. The Company has not recorded any impairment related to goodwill.

Intangible Assets, Net

Intangible assets include finite-lived product technology, customer relationships, licenses and trade names and indefinite-lived in-process research and development. Intangible assets consisted of the following (in thousands of dollars):


	June 30, 2026						December 31, 2025						Weighted Average Remaining Amortization Period (Years)
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Percepta product technology	$	16,000	$	(12,000)	$	4,000	$	16,000	$	(11,467)	$	4,533	3.8
Prosigna product technology	4,120		(1,808)		2,312		4,120		(1,671)		2,449		8.4
Decipher product technology	97,300		(48,301)		48,999		97,300		(43,558)		53,742		6.0
Decipher trade names	4,000		(4,000)		—		4,000		(3,843)		157
C2i developed technology	31,500		(4,111)		27,389		25,300		(3,233)		22,067		13.1
Total finite-lived intangibles	152,920		(70,220)		82,700		146,720		(63,772)		82,948		8.3
In-process research and development	—		—		—		6,200		—		6,200
Total intangible assets	$	152,920	$	(70,220)	$	82,700	$	152,920	$	(63,772)	$	89,148

Acquisition-related intangibles are generally finite-lived and are carried at cost less accumulated amortization. Amortization of the finite-lived intangible assets is recognized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized. During the second quarter of 2026 following the launch of TrueMRD, in-process research and development intangibles of $6.2 million were reclassified to C2i developed technology intangibles and is being amortized over its estimated useful life.

Amortization of $3.2 million and $3.3 million was recognized for the three months ended June 30, 2026 and 2025, respectively, and an expense of $6.4 million and $6.5 million was recognized for the six months ended June 30, 2026 and 2025, respectively.

The estimated future aggregate amortization expense as of June 30, 2026 is as follows (in thousands of dollars):


Year Ending December 31,	Amounts
2026 remainder of year	$	6,464
2027	12,928
2028	12,928
2029	12,928
2030	12,128
Thereafter	25,324
Total	$	82,700

Impairment of Assets

The Company concluded, during the second quarter of 2025, that the long-lived assets of the Veracyte SAS asset group were not recoverable. As a result, the Company recorded a $20.5 million non-cash impairment charge for the three and six months ended December 31, 2025. The impairment related primarily to the Company's right-of-use assets; property, plant, and

equipment; and certain tax credits. The impairment is included within the impairment of assets in the consolidated statement of operations.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands of dollars):


	June 30, 2026		December 31, 2025
Accrued compensation expenses	$	25,131	$	27,459
Accrued other	22,546		21,342
Total accrued liabilities	$	47,677	$	48,801